---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255166"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:21:15.154022+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track

## Summary
- Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.
- Net loss of $17.5M for Q3 2024 vs $22.8M in Q3 2023 (prior year included $13.3M non-cash charge).
- IPO in Sep 2024 raised ~$362M gross from 20.125M shares at $18.00; listed on Nasdaq as BCAX.
- Pivotal Phase 2/3 trial FORTIFI-HN01 of ficerafusp alfa in 1L R/M HNSCC expected to start late Q4 2024 or early Q1 2025.
- Phase 1/1b data showed 64% ORR, 18% CR, median PFS 9.8 months in frontline HPV-negative R/M HNSCC.

## SEC filing metadata
- accession: 0001193125-24-255166
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/0001193125-24-255166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/d793839d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255166
- JSON: https://secwatch.observer/filing/0001193125-24-255166.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.